UPCC 53418: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized open label phase III trial (BELINDA)

Enrolling By Invitation
99 years or below
All
1 Location

Brief description of study

We would like to rely on the WIRB as IRB of record for this study. The main purpose of this study is to find out if the investigational therapy tisagenlecleucel (i.e. CTL019, CART-19, or Kymriah®) is safe and has beneficial effects in people who have relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 832184
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research